Antitrust Antitrust

Pfizer, Flynn Pharma didn’t collude over epilepsy-drug pricing, UK judge hears

By Simon Zekaria
  • 21 Nov 2023 16:39
  • 21 Nov 2023 16:39
Pfizer and Flynn Pharma didn’t collude to excessively hike the price of an epilepsy treatment, a specialist in drug-market accounting told a judge today, as the UK antitrust court heard further argument that the Competition and Markets Authority's infringement case against the drugmakers was flawed.
In an ongoing appeal trial,

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Simon Zekaria

Senior Correspondent

Simon Zekaria is a senior correspondent in London, covering UK regulation. Prior to joining MLex, Simon reported on business news for The Wall Street Journal, including on telecommunications, media, technology and consumer affairs. Simon was also a writer for the WSJ on diverse subjects such as Brexit, UK politics and global sport. Simon was previously a correspondent on competition issues and European politics for Thomson Reuters and Agence France-Presse in Brussels. Simon is a graduate of Edinburgh University, with Masters degrees in literature and law. A French speaker, he has studied at the Sorbonne University, Paris.

Discover MLex

Stay on top of global regulatory developments

Latest News